Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
about
Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab.Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.Digging deeper in relapsed acute lymphoblastic leukemia: impact of MRD status on outcome in second remission.Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.Blinatumomab bridges the gap between leukemia and immunity.
P2860
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Long-term relapse-free surviva ...... acute lymphoblastic leukemia.
@en
Long-term relapse-free surviva ...... acute lymphoblastic leukemia.
@nl
type
label
Long-term relapse-free surviva ...... acute lymphoblastic leukemia.
@en
Long-term relapse-free surviva ...... acute lymphoblastic leukemia.
@nl
prefLabel
Long-term relapse-free surviva ...... acute lymphoblastic leukemia.
@en
Long-term relapse-free surviva ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P1433
P1476
Long-term relapse-free surviva ...... acute lymphoblastic leukemia.
@en
P2093
Andreas Viardot
Dorothea Wessiepe
Gerhard Zugmaier
Heinz A Horst
Matthias Klinger
Matthias Stelljes
Max S Topp
Monika Brüggemann
Nicola Gökbuget
Oliver G Ottmann
P2860
P304
P356
10.3324/HAEMATOL.2016.153957
P577
2017-01-12T00:00:00Z